Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, announces that, in response to the notice received from Aditxt Inc. (“Aditxt”) on May 17, 2025, the Company has delivered formal notice to Aditxt to terminate the arrangement agreement (the “Arrangement Agreement”) dated April 1, 2024 (as amended) between the Company, Aditxt and its wholly-owned subsidiary, Adivir, Inc. (“Adivir”). Such termination is effective as of May 30, 2025.
Read the full article: Appili Therapeutics Announces Formal Termination of Arrangement Agreement with Aditxt Inc. //
Source: https://www.globenewswire.com/news-release/2025/05/30/3090987/0/en/Appili-Therapeutics-Announces-Formal-Termination-of-Arrangement-Agreement-with-Aditxt-Inc.html